Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
News articles
6/25/2026
Lindahl recognised in IP Stars 2026
Lindahl advances to Tier 2 in Copyright & related rights in IP Stars 2026, retains strong rankings in trade mark law, and sees several lawyers recognised with individual awards.
-
Cases and transactions
6/23/2026
Lindahl acts as legal adviser to Medivir in a private placement of approximately 140 MSEK
Lindahl acted as legal adviser to Medivir in connection with an oversubscribed private placement of SEK 140 million for the clinical development of the drug candidate MIV-711.
-
Knowledge
6/15/2026
Properly prepared — contract law in the new security landscape
Preparedness laws such as the Rationing Act and the Requisition Act can alter your contracts from one day to the next. Lindahl cuts through the terminology in the new security landscape.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
Read more news and insights?
